NRX Pharmaceuticals, Inc.

Item 7.01 Regulation FD Disclosure. On September 8, 2026, representatives of NRx Pharmaceuticals, Inc. (the “Company”) used the investor presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K in connection with presentations and meetings with investors and other persons. The Company may continue to use the investor presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and other persons. The information contained in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits. Exhibit Description No. ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 99.1 Investor Presentation 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.